Inovio Pharmaceuticals Competitors and Similar CompaniesClear all

Inovio Pharmaceuticals's competitors and similar companies include Immunai, Evotec, Vertex Pharmaceuticals and BioMarin Pharmaceutical.

	Inovio Pharmaceuticals Inovio Pharmaceuticals is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid immunotherapies and vaccines.	Immunai Immunai is a biotechnology company specializing in immune cell data analysis for drug development.	Evotec Evotec is a biotechnology company that provides drug discovery and development services.	Vertex Pharmaceuticals Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and producing medicines.	BioMarin Pharmaceutical BioMarin develops and provides innovative biopharmaceuticals for serious diseases and medical conditions.
Founding Date	Founding Date 1979	Founding Date 2018	Founding Date 1993	Founding Date 1989	Founding Date 1997
Type	Type Public	Type Private	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech clinical research machine learning oncology platform	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Plymouth Meeting, US HQ San Diego, US San Diego, US	Locations New York, US HQ Prague, CZ Ness Ziona, IL Tel Aviv, IL Zurich, CH	Locations Hamburg, DE HQ Lyon, FR Toulouse, FR Göttingen, DE Halle (Westfalen), DE Köln, DE Munich, DE see more	Locations Boston, US HQ St Leonards, AU Wien, AT Bruxelles, BE São Paulo, BR Toronto, CA Praha, CZ see more	Locations San Rafael, US HQ Martínez, AR Crows Nest, AU Sao Paulo, BR Bogotá, CO Kronberg Im Taunus, DE Wanchai, HK see more
Employees	Employees 2811% increase	Employees 1873% increase	Employees 4,766	Employees 5,40013% increase	Employees 3,0015% increase
Valuation ($)	Valuation ($) 144.4 m	Valuation ($) 1.2 b	Valuation ($) 1.4 b	Valuation ($) 121.4 b	Valuation ($) 13.3 b
Financial
Revenue (est.)	Revenue (est.) $65.3k (FY, 2025)	Revenue (est.) N/A	Revenue (est.) €788.4m (FY, 2025)	Revenue (est.) $12b (FY, 2025)	Revenue (est.) $3.2b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods €622.9m (FY, 2025)	Cost of goods $1.7b (FY, 2025)	Cost of goods $717.4m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit €231.1m (FY, 2025)	Gross profit $10.4b (FY, 2025)	Gross profit $2.5b (FY, 2025)
Net income	Net income ($84.9m) (FY, 2025)	Net income N/A	Net income (€103.5m) (FY, 2025)	Net income N/A	Net income $348.9m (FY, 2025)
Operating ⚠
Patents Issued	Patents Issued 620 (FY, 2016)	Patents Issued N/A	Patents Issued N/A	Patents Issued N/A	Patents Issued 1.2 k (FY, 2016)
Products	Products N/A	Products N/A	Products 140 (FY, 2023)	Products 6 (FY, 2022)	Products N/A
Funding
Total funding raised	Total funding raised $ 202.6m	Total funding raised $ 295m	Total funding raised $ 993.6m	Total funding raised $ 2.4m	Total funding raised N/A